Apimeds Pharmaceuticals CEO Erik Emerson Discusses Purified Bee Venom for Knee Osteoarthritis and Other Inflammatory Conditions episode artwork

EPISODE · Jun 11, 2025 · 29 MIN

Apimeds Pharmaceuticals CEO Erik Emerson Discusses Purified Bee Venom for Knee Osteoarthritis and Other Inflammatory Conditions

from WTR Small-Cap Spotlight · host Water Tower Research

Send us Fan MailOn this week’s WTR Small-Cap Spotlight, we speak with Apimeds CEO Erik Emerson about the newly NYSE listed company and the development of Apitox, a purified honeybee venom, for knee osteoarthritis and multiple sclerosis. We discuss the therapeutic properties of bee venom and the clinical/regulatory plans to bring Apitox to the US market. Listen to learn more about Apimeds and its novel approach to treat inflammatory pain.You can listen to this episode and more on the WTR Biotech Spotlight at the links below!Apple: https://podcasts.apple.com/us/podcast/wtr-biotech-spotlight/id1795488592Spotify: https://open.spotify.com/episode/7KUMWuGavyAuDEs2527rp2?si=22adef2e0f304634

Episode metadata supplied by the publisher feed · Published Jun 11, 2025

Embed this episode

NOW PLAYING

Apimeds Pharmaceuticals CEO Erik Emerson Discusses Purified Bee Venom for Knee Osteoarthritis and Other Inflammatory Conditions

0:00 29:37

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of WTR Small-Cap Spotlight?

This episode is 29 minutes long.

When was this WTR Small-Cap Spotlight episode published?

This episode was published on June 11, 2025.

Can I download this WTR Small-Cap Spotlight episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!